Etomidate Induction in Hysteroscopic Surgery

Randomized Controlled Study of Etomidate Induction in Hysteroscopic Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05520645

Enrollment

200

Registered

2022-08-30

Start date

2022-08-25

Completion date

2023-12-30

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Etomidate Induced Dose, Hysteroscopic Surgery

Brief summary

This study intends to study the optimal dose induced by etomidate in outpatients undergoing painless hysteroscopic surgery. At present, the dosage in the user manual is 0.1-0.3mg/kg. In clinical use, it is found that 0.1mg/kg often fails to achieve sedative effect, and 0.3mg/kg is prone to muscle twitching. Therefore, three groups of doses of 0.15mg/kg, 0.2mg/kg and 0.25mg/kg are set. It is hoped that this study will provide a basis for clinical evaluation of etomidate in anesthesia induction of hysteroscopic surgery.

Interventions

DRUGetomidate

use etomidate for anesthesia induction in hysteroscopic surgery

DRUGpropofol

use propofol for anesthesia induction in hysteroscopic surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

Patients to undergo hysteroscopic surgery

Exclusion criteria

Hemo-dynamically unstable patients Allergic to egg protein Patients with epilepsy

Design outcomes

Primary

Measure	Time frame	Description
Mean Arterial Pressure	Change in Mean Arterial Pressure(MAP) in mm of Hg from baseline value every 5 minutes for 30 minutes	Mean value of Mean Arterial Pressures
Heart rate per minute	Change in Heart rate per minute from baseline value every five minutes for 30 minutes	Mean of Heart rate per minute at above mentioned time intervals was measured and any study drug causing bradycardia

Secondary

Measure	Time frame	Description
Myoclonic movements	60 seconds after injection of study drug	% of cases with Myoclonic movements
Post Operative Nausea and Vomiting	Throughout entire study estimated to take 1 month to complete	% of cases with any treatment for Post Operative Nausea and Vomiting
any oxygen saturation event below 85% by pulse oximetry	Throughout entire study estimated to take 1 month to complet	% of cases with any oxygen saturation event below 85% by pulse oximetry

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026